Filtered By:
Condition: Pregnancy
Management: Funding
This page shows you your search results in order of date.
Order by Relevance | Date
Total 25 results found since Jan 2013.
Science ’s 2022 Breakthrough of the Year: A telescope’s golden eye sees the universe anew
html { scroll-behavior: smooth; } .news-article-content--featured>.bodySection>.mb-2x:not(:first-of-type) { display: none; } h3 { scroll-margin-top: 5rem; } .parent-section h3, .subsection h3 { font-size: 1.375rem; line-height: 1.875rem; } .news-article-content-footer h2 { display: none; } .toc img { padding-bottom: 16px; transition: opacity .25s; } .toc img:hover { opacity: 60%; } .toc .image-grid img { padding-bottom: 16px; padding-top: 16px; } .image-grid .news-article__figure__image__wrapper:before, .image-grid .news-article__figure__image__wrapper:after { display: none; } .news-article-content sectio...
Source: ScienceNOW - December 15, 2022 Category: Science Source Type: news
Impact of universal testing and treatment on sexual risk behaviour and herpes simplex virus type 2: a prespecified secondary outcomes analysis of the HPTN 071 (PopART) community-randomised trial
Lancet HIV. 2022 Nov;9(11):e760-e770. doi: 10.1016/S2352-3018(22)00253-3.ABSTRACTBACKGROUND: Comprehensive HIV prevention strategies have raised concerns that knowledge of interventions to reduce risk of HIV infection might mitigate an individual's perception of risk, resulting in riskier sexual behaviour. We investigated the prespecified secondary outcomes of the HPTN 071 (PopART) trial to determine whether a combination HIV prevention strategy, including universal HIV testing and treatment, changed sexual behaviour; specifically, we investigated whether there was evidence of sexual risk compensation.METHODS: HPTN 071 (Po...
Source: Herpes - November 4, 2022 Category: Infectious Diseases Authors: Ethan Wilson Deborah Donnell Timothy Skalland Sian Floyd Ayana Moore Nomtha Bell-Mandla Justin Bwalya Nkatya Kasese Rory Dunbar Kwame Shanaube Barry Kosloff Oliver Laeyendecker Yaw Agyei Graeme Hoddinott Peter Bock Sarah Fidler Richard Hayes Helen Ayles H Source Type: research
Top Local Changemakers Addressing Health Equity Gaps Across the U.S. Named Johnson & Johnson Health Equity Innovation Challenge Awardees
NEW BRUNSWICK, N.J., June 14, 2022 – After an extensive search for the top changemakers in six key U.S. cities, Johnson & Johnson today announced the 14 awardees of its Health Equity Innovation Challenge. The awardees, who possess lived experience and a deep understanding of the communities they serve, were selected for their work in generating solutions to help close racial health and mortality gaps in six cities where Black and Brown individuals experience significant health inequities: Chicago, Detroit, Los Angeles, New Orleans, New York City and Philadelphia.The Health Equity Innovation Challenge was created by J...
Source: Johnson and Johnson - June 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
Lancet Respir Med. 2022 May 23:S2213-2600(22)00088-1. doi: 10.1016/S2213-2600(22)00088-1. Online ahead of print.ABSTRACTBACKGROUND: Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in preventing progression to mechanical ventilation or death in hospitalised patients with COVID-19.METHODS: In this randomised, double-blind, double placebo-controlled trial, patients were enrolled at 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites)...
Source: Respiratory Care - May 26, 2022 Category: Respiratory Medicine Authors: Cameron R Wolfe Kay M Tomashek Thomas F Patterson Carlos A Gomez Vincent C Marconi Mamta K Jain Otto O Yang Catharine I Paules Guillermo M Ruiz Palacios Robert Grossberg Michelle S Harkins Richard A Mularski Nathaniel Erdmann Uriel Sandkovsky Eyad Almasri Source Type: research
10 Black Americans Who Have Led COVID-19 Response
By The Editorial Team,
IntraHealth InternationalFebruary 22, 2022Meet 10 Black American leaders who are shaping local and national COVID-19 response. These scientists, researchers, policymakers, teachers, and more have seen first-hand how the pandemic exacerbates racial disparities in health. In the US, Black Americans have died from COVID-19 at1.4 times the rate of white people.Today we’re highlighting these leaders as they work to protect their communities and inform our global response to the pandemic.Christopher BarnesAssistant professor, Department of Biology at Stanford UniversityWhen COVID-19 began, Bar...
Source: IntraHealth International - February 17, 2022 Category: International Medicine & Public Health Authors: kseaton Tags: COVID-19 Health Workers Source Type: news
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial
Lancet Respir Med. 2021 Oct 18:S2213-2600(21)00384-2. doi: 10.1016/S2213-2600(21)00384-2. Online ahead of print.ABSTRACTBACKGROUND: Functional impairment of interferon, a natural antiviral component of the immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to compare the efficacy of interferon beta-1a in combination with remdesivir compared with remdesivir alone in hospitalised patients with COVID-19.METHODS: We did a double-blind, randomised, placebo-controlled trial at 63 hospitals across five countries (Japan, Mexico, Singapore, South Korea, and the USA). Eligible patients were hospita...
Source: Respiratory Care - October 21, 2021 Category: Respiratory Medicine Authors: Andre C Kalil Aneesh K Mehta Thomas F Patterson Nathaniel Erdmann Carlos A Gomez Mamta K Jain Cameron R Wolfe Guillermo M Ruiz-Palacios Susan Kline Justino Regalado Pineda Anne F Luetkemeyer Michelle S Harkins Patrick E H Jackson Nicole M Iovine Victor F Source Type: research
Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa
Discussions are ongoing with the U.S. Food and Drug Administration regarding the approval of the vaccine regimen in the U.S. WHO Prequalification is often a prerequisite for national registrations of new vaccines and medicines in developing countries. Johnson & Johnson now looks forward to collaborating with the WHO’s African Vaccine Regulatory Forum (AVAREF) to progress national registrations of the Company’s Ebola vaccine regimen. The Company’s Ebola vaccine regimen is designed to be used proactively to induce immunity against Ebola virus disease in adults and children. Johnson & Johnson’s Commitment to E...
Source: Johnson and Johnson - May 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial
Publication date: Available online 19 February 2020Source: The LancetAuthor(s): Håvard Ove Skjerven, Eva Maria Rehbinder, Riyas Vettukattil, Marissa LeBlanc, Berit Granum, Guttorm Haugen, Gunilla Hedlin, Linn Landrø, Benjamin J Marsland, Knut Rudi, Kathrine Dønvold Sjøborg, Cilla Söderhäll, Anne Cathrine Staff, Kai-Håkon Carlsen, Anna Asarnoj, Karen Eline Stensby Bains, Oda C Lødrup Carlsen, Kim M Advocaat Endre, Peder Annæus Granlund, Johanne Uthus HermansenSummaryBackgroundSkin emollients applied during early infancy could prevent atopic dermatitis, and early complementary food introduction might reduce food all...
Source: The Lancet - February 21, 2020 Category: General Medicine Source Type: research
Myeloid-Derived Suppressor Cells: Ductile Targets in Disease
Discussion
MDSCs violently emerge in pathological conditions in an attempt to limit potentially harmful immune and inflammatory responses. Mechanisms supporting their expansion and survival are deeply investigated in cancer, in the perspective to reactivate specific antitumor responses and prevent their contribution to disease evolution. These findings will likely contribute to improve the targeting of MDSCs in anticancer immunotherapies, either alone or in combination with immune checkpoint inhibitors. New evidence indicates that the expansion of myeloid cell differentiation in pathology is subject to fine-tuning, as its...
Source: Frontiers in Immunology - May 2, 2019 Category: Allergy & Immunology Source Type: research
The Human Upper Respiratory Tract Epithelium Is Susceptible to Flaviviruses
In this study, we exposed apically well-differentiated human NECs cultured at the ALI to the related flaviviruses ZIKV, JEV, WNV, and Usutu virus (USUV). We selected these viruses due to the recent increasing evidences of potential threat to humans (Cadar et al., 2017; Simonin et al., 2018). We show that NECs are particularly susceptible to JEV and WNV infection and to other flaviviruses included in this study. Infection with each virus led to shedding of infectious virus particles through the apical and basolateral surfaces and triggered host mechanisms at the level of inflammatory and antiviral mediators....
Source: Frontiers in Microbiology - April 15, 2019 Category: Microbiology Source Type: research
Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
This study was carried out in accordance with the recommendations of The London School of Hygiene & Tropical Medicine (LSHTM) Research Ethics Committee (Ref. 6123) and the National Research Ethics Service (NRES) London-Bloomsbury Research Ethics Committee (REC ref. 11/10/1760, IRAS ID: 77765), with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the LSHTM Research Ethics Committee and the NRES London-Bloomsbury Research Ethics Committee.
Author Contributions
JC, HD, LN, EL, and ER devised the study ...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research
The Florence Statement on Triclosan and Triclocarban
Author Affiliations open
1Biodesign Center for Environmental Security, Arizona State University, Tempe, Arizona, USA
2Green Science Policy Institute, Berkeley, California, USA
3Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA
4Environmental Working Group, Washington, District of Columbia, USA
5Department of Civil, Environmental, and Geo-Engineering, University of Minnesota, Minneapolis, Minnesota, USA
6Medical University of South Carolina, Department of Public Health Sciences, Charleston, South Carolina, USA
7Health Research Communicati...
Source: EHP Research - June 20, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Brief Communication Source Type: research
Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study
This study is registered with ClinicalTrials.gov, number NCT01052480. Findings Between Jan 13, 2011, and March 2, 2015, 113 participants were screened for eligibility and 98 were randomly assigned from 20 out of 29 participating sites. Of the participants with confirmed influenza (by PCR), 28 (67%) of 42 in the plasma plus standard care group normalised their respiratory status by day 28 compared with 24 (53%) of 45 participants on standard care alone (p=0·069). The hazard ratio (HR) comparing plasma plus standard care with standard care alone was 1·71 (95% CI 0·96–3·06). Six participants died, one (2%) from the plas...
Source: The Lancet Respiratory Medicine - May 16, 2017 Category: Respiratory Medicine Source Type: research
Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial
Publication date: Available online 5 May 2017 Source:The Lancet Respiratory Medicine Author(s): Patricia van Velzen, Gerben ter Riet, Paul Bresser, Jeroen J Baars, Bob T J van den Berg, Jan W K van den Berg, Paul Brinkman, Jennece W F Dagelet, Johannes M A Daniels, Dewi R G L Groeneveld-Tjiong, René E Jonkers, Coen van Kan, Frans H Krouwels, Karin Pool, Arjan Rudolphus, Peter J Sterk, Jan M Prins Background Antibiotics do not reduce mortality or short-term treatment non-response in patients receiving treatment for acute exacerbations of COPD in an outpatient setting. However, the long-term effects of antibiotics are unkn...
Source: The Lancet Respiratory Medicine - May 6, 2017 Category: Respiratory Medicine Source Type: research
